1. Current Concepts in Antifungal Pharmacology
Russell E. Lewis, PharmD 
Mayo Clinic Proceedings 
Volume 86, Issue 8, Pages (August 2011)
DOI: /mcp
Copyright © 2011 Mayo Foundation for Medical Education and Research Terms and Conditions

2. FIGURE 1 Timeline of systemic antifungal drugs.
Mayo Clinic Proceedings  , DOI: ( /mcp )
Copyright © 2011 Mayo Foundation for Medical Education and Research Terms and Conditions

3. FIGURE 2
Sites of action and mechanisms of systemic antifungal agents. FKS1, FKS2 catalytic subunits of the glucan synthase complex are the putative target binding site of echinocandins. Rho is a cell wall-regulating protein. *Isavuconazole is still in phase 3 trials.
Mayo Clinic Proceedings  , DOI: ( /mcp )
Copyright © 2011 Mayo Foundation for Medical Education and Research Terms and Conditions

4. FIGURE 3
Spectrum of action of systemic antifungal agents. Solid blocks represent species in which the antifungal agent has demonstrated microbiological and clinical efficacy. Blocks with dotted lines indicate fungal genera/species in which resistance is common. AMB = amphotericin; ANID = anidulafungin; CAS = caspofungin; 5-FC = flucytosine; FLU = fluconazole; ITRA = itraconazole; MICA = micafungin; POSA = posaconazole; VORI = voriconazole.
Mayo Clinic Proceedings  , DOI: ( /mcp )
Copyright © 2011 Mayo Foundation for Medical Education and Research Terms and Conditions

5. FIGURE 4
Common toxicities of antifungal agents. CNS = central nervous system; 5-FC = flucytosine; GI = gastrointestinal; IV = intravenous; QTc = corrected QT interval.
Mayo Clinic Proceedings  , DOI: ( /mcp )
Copyright © 2011 Mayo Foundation for Medical Education and Research Terms and Conditions